Amarin to Host Conference Call on October 16, 2013 to Discuss Results of FDA Advisory Committee Meeting on ANCHOR Supplemental

Amarin to Host Conference Call on October 16, 2013 to Discuss Results of FDA
Advisory Committee Meeting on ANCHOR Supplemental New Drug Application (sNDA)
for Vascepa(R)

    Approval of the ANCHOR sNDA Would Expand Use of Vascepa to Include the
Treatment of Patients with High Triglycerides (≥200 mg/dL and <500 mg/dL) with
                              Mixed Dyslipidemia

BEDMINSTER, N.J., and DUBLIN, Ireland, Oct. 9, 2013 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, today announced details for its planned conference call to discuss the
results of the U.S. Food and Drug Administration (FDA) advisory committee
meeting in connection with the FDA's review of the supplemental New Drug
Application (sNDA) seeking approval for the use of Vascepa® (icosapent ethyl)
capsules in the proposed ANCHOR indication, as an adjunct to diet in the
treatment of adult patients with high triglycerides (TG ≥200 mg/dL and <500
mg/dL) with mixed dyslipidemia. Members of Amarin senior management will host
this event on Wednesday, October 16, 2013, at 7:00 p.m. ET, following the
conclusion of the ANCHOR advisory committee meeting scheduled for earlier that
day.

To participate in the call, please dial 877-407-8033 within the United States
or 201-689-8033 from outside the United States. A replay of the call will be
made available for a period of two weeks following the conference call. To
hear a replay of the call, dial 877-660-6853 (inside the United States) or
201-612-7415 (outside the United States). A replay of the call will also be
available through the company's website shortly after the call. For both
dial-in numbers please use conference ID 100205. The conference call can also
be heard live via the investor relations section of the company's website at
www.amarincorp.com.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit
www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

About FDA advisory committee meetings

Advisory committees provide FDA with independent advice from outside experts
on issues related to human and veterinary drugs, vaccines and other biological
products, medical devices, and food. In general, advisory committees include a
chair, multiple members, plus a consumer, industry, and sometimes a patient
representative. Additional experts with special knowledge may be added for
individual committee meetings as needed. Recommendations from the advisory
committee will be considered by the FDA in its review, but the FDA is not
bound to follow them in determining whether to approve an application.

Availability of other information about Amarin

Investors and others should note that we communicate with our investors and
the public using our company website (www.amarincorp.com), our investor
relations website (http://www.amarincorp.com/investor-splash.html), including
but not limited to investor presentations and investor FAQs, Securities and
Exchange Commission filings, press releases, public conference calls and
webcasts. The information that we post on these channels and websites could be
deemed to be material information. As a result, we encourage investors, the
media, and others interested in Amarin to review the information that we post
on these channels, including our investor relations website, on a regular
basis. This list of channels may be updated from time to time on our investor
relations website and may include social media channels. The contents of our
website or these channels, or any other website that may be accessed from our
website or these channels, shall not be deemed incorporated by reference in
any filing under the Securities Act of 1933.

CONTACT: Joseph Bruno
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.